Delivery Order SPE2DB20D3505-SPE2DB25FU4H3

Award Date 4/18/25
Potential Completion Date 4/21/25
Potential Value $31K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,020.88, is a delivery order for the medical product "ADBRY 300 MG/2 ML AUTOINJECTOR 2ML". The contract has an ultimate completion date of April 10, 2025 and is a firm fixed-price contract. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,150.03, is for the delivery of ADBRY 300 MG/2 ML AUTOINJECTOR 2ML, a medical product. The contract has an ultimate completion date of April 4, 2025 and is a firm fixed-price delivery order. This award is part of AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,939.82, is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical. The IDC, valued at $999,999,999, serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,020.88, is for the delivery of a specific pharmaceutical product, ADBRY 300 MG/2 ML AUTOINJECTOR 2ML. The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 11, 2025. The contract is not set aside for any specific business category. Amerisourcebergen Drug Corp...
This federal contract award, valued at $5,716.64, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the supply of ADBRY 300 MG/2 ML AUTOINJECTOR 2ML, a medical product, with a completion date of February 19, 2025. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award is associated with a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $19,364.74 firm-fixed-price delivery order contract is for the provision of ADBRY 150 MG/ML SYRINGEML, a pharmaceutical product. This award is under Amerisourcebergen's existing $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for supplying a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,083.54 firm fixed-price contract is for the delivery of ADBRY 300 MG/2 ML AUTOINJECTOR 2ML, a medical supply. The contract has an ultimate completion date of May 13, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
This federal contract award for $5,364.44 was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the medical product "ADBRY 150 MG/ML SYRINGEML" with a completion date of May 23, 2024. The contract is a firm fixed price award with no set-aside designation, indicating open competition. AmerisourceBergen holds a substantial Indefinite Delivery Contract...
This federal contract award, valued at $5,617.92, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ADBRY 150 MG/ML syringes and has an ultimate completion date of August 7, 2023. The contract type is Delivery Order with a Firm Fixed Price pricing structure. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant...
This federal contract award, valued at $45,082.92, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by Amerisourcebergen with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to...
  • SPE2DB20D3505
    Indefinite Delivery Contract
  • SPE2DB20D3505-SPE2DB25FU4H3
    Delivery Order

This federal contract award, valued at $31,354.05, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of ADBRY 300 MG/2 ML AUTOINJECTOR 2ML, a pharmaceutical product. This award is not associated with a set-aside program.

AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00. This prime contract, designated as SPE2DX, provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. The IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard.

Generated 7/18/25, 9:46 AM